GLP-2
An intestinal growth hormone that repairs and reinforces the gut lining, validated clinically through its stabilized analog teduglutide.
GLP-2 is a 33-amino-acid endogenous proglucagon-derived peptide secreted by intestinal L-cells in response to nutrient ingestion. It acts as a trophic and protective hormone for the intestinal epithelium, promoting mucosal growth, barrier integrity, and nutrient absorption. Because native GLP-2 is degraded within minutes, its clinical application is realized through the DPP-IV-resistant analog teduglutide (Gattex/Revestive), FDA-approved in 2012 for short bowel syndrome-associated intestinal failure.
Class
Endogenous 33-amino-acid proglucagon-derived peptide
Half-life
~7 minutes for native GLP-2 due to rapid DPP-IV degradation; stabilized analogs (teduglutide, apraglutide) are far longer-acting.
Routes
Subcutaneous
Category
Healing & Recovery
Researched benefits
What it's studied for
Gut lining repair
GLP-2 promotes enterocyte proliferation while inhibiting apoptosis, increasing villus height and crypt depth. In mice, GLP-2 analogs produced measurable increases in small intestine weight, villus height, and crypt depth.
Intestinal barrier integrity
It strengthens epithelial tight junctions and reduces intestinal permeability, supporting a more robust mucosal barrier against luminal insults.
Enhanced nutrient absorption
By expanding absorptive surface area and supporting intestinal adaptation, GLP-2 receptor agonism reduces dependence on parenteral nutrition in short bowel syndrome, with teduglutide sustaining roughly 50% reductions in parenteral support over the long term.
Intestinal adaptation and motility
Signaling through GLP-2R on subepithelial myofibroblasts and enteric neurons, GLP-2 modulates gut motility and collectively supports absorptive capacity and adaptation of the remaining bowel.
Gut microbiota modulation
The long-acting analog apraglutide promoted early maturation of altered gut microbiota in short bowel syndrome, reducing compositional variability and shifting bacterial populations toward a more balanced ecosystem.
Mechanism
How it works
GLP-2 is released from intestinal L-cells after nutrient ingestion and binds the GLP-2 receptor (GLP-2R), which is expressed on intestinal subepithelial myofibroblasts and enteric neurons rather than directly on enterocytes. Receptor activation triggers downstream signals that drive enterocyte proliferation and reduce apoptosis, producing net growth of the intestinal epithelium reflected in greater villus height and crypt depth.
Beyond stimulating mucosal growth, GLP-2 strengthens epithelial tight junctions and reduces intestinal permeability, reinforcing barrier function. It also modulates gut motility, and together these actions promote intestinal adaptation and improve the absorptive capacity of the bowel.
Native GLP-2 has a plasma half-life of only about 7 minutes because it is rapidly cleaved by the enzyme DPP-IV, which is why the endogenous peptide is not viable as a therapeutic. Clinical translation is achieved with DPP-IV-resistant analogs such as teduglutide and apraglutide, which retain GLP-2R agonism while circulating far longer, enabling sustained trophic effects on the intestine.
Evidence
Research & clinical studies (6)
Reduction of Parenteral Nutrition and Hydration Support and Safety With Long-Term Teduglutide Treatment in Patients With Short Bowel Syndrome-Associated Intestinal Failure: STEPS-3 Study
Teduglutide sustained parenteral nutrition reductions of approximately 50% from baseline over up to 42 months, with two patients achieving full enteral autonomy and a consistent safety profile.
PMID 29761915PERCC1-associated enteropathy: Diagnostic challenges and enteral autonomy achieved with teduglutide
A patient with a novel PERCC1 mutation causing congenital enteropathy achieved independence from parenteral nutrition following teduglutide treatment, suggesting benefit in certain genetic enteropathies.
PMID 42110144From childhood to adulthood in chronic intestinal failure: A nationwide study
Among patients transitioning from childhood-onset chronic intestinal failure to adult care, GLP-2 analogues (teduglutide) were the only intervention significantly associated with decreased dependence on home parenteral nutrition.
PMID 42105609Early ecological changes in intestinal microbiota with the long-acting GLP-2 analog apraglutide in short bowel syndrome
Apraglutide promoted early maturation of the altered gut microbiota by reducing compositional variability and shifting bacterial populations toward a more balanced ecosystem, without changing overall diversity.
PMID 41903849Prostaglandin E2 stimulates GLP-1 and GLP-2 secretion and reduces glucose absorption in the perfused rat small intestine
PGE2 stimulated secretion of both GLP-1 and GLP-2 from the small intestine while simultaneously reducing glucose absorption, illuminating a physiological role in intestinal hormone release.
PMID 42011909A Long-Acting Glucagon-like Peptide 2 Protracted by Coomassie Brilliant Blue to Enhance Intestinal Growth in Mice
A GLP-2 modified with Coomassie brilliant blue achieved significantly extended circulation time while retaining efficacy, producing enhanced intestinal growth including increased small intestine weight, villus height, and crypt depth versus controls.
PMID 41961990Safety
Side effects & considerations
Contraindications & cautions
- Active or prior cancer history
- Pregnancy or nursing
GLP-2 carries a moderate risk profile in research contexts. Because it is a trophic (growth-promoting) hormone, particular caution applies to individuals with a history of malignancy. Consult a qualified healthcare professional before use.
FAQ
GLP-2 — common questions
What is GLP-2?
GLP-2 (glucagon-like peptide-2) is a 33-amino-acid endogenous proglucagon-derived peptide secreted by intestinal L-cells in response to nutrient ingestion. It functions as a trophic and protective hormone for the intestinal epithelium, supporting mucosal growth, barrier integrity, and nutrient absorption via the GLP-2 receptor on subepithelial myofibroblasts and enteric neurons.
What is GLP-2 primarily studied for?
It is primarily studied for gut lining repair, intestinal integrity, barrier function, and anti-inflammatory effects, with the strongest clinical evidence in short bowel syndrome-associated intestinal failure.
Why is native GLP-2 not used as a drug?
Native GLP-2 has a plasma half-life of only about 7 minutes because it is rapidly degraded by the enzyme DPP-IV. Clinical application is instead achieved through DPP-IV-resistant analogs such as teduglutide and apraglutide.
Is there an FDA-approved GLP-2 therapy?
Yes. Teduglutide (Gattex/Revestive), a stabilized GLP-2 analog, was approved by the FDA on August 30, 2012 for short bowel syndrome-associated intestinal failure. It is a prescription medication, not a general wellness product.
What does the research show about GLP-2?
Clinical studies show GLP-2 receptor agonism, via teduglutide, sustains roughly 50% reductions in parenteral nutrition support and can enable enteral autonomy in short bowel syndrome. Preclinical work confirms it drives intestinal growth, and newer analogs like apraglutide also favorably reshape the gut microbiota.
What are the side effects and contraindications of GLP-2?
GLP-2 has a moderate risk profile. Reported contraindications include a history of active cancer and pregnancy or nursing. Because it promotes tissue growth, medical supervision is important, especially with any malignancy history.
How is GLP-2 administered?
GLP-2 and its clinical analogs are administered subcutaneously.
